/
Core Rare Disease Product Candidates Setrusumab (BPS-804/UX143) for the Treatment of Osteogenesis Imperfecta Top-line Data from Setrusumab Phase 3 Orbit and Cosmic Studies. We do not know whether our planned clinical trials will begin on time or be completed on schedule, if at all.
The business is unprofitable at the operating level (-8021.40% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$31M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$500K
Net Income (TTM)
-$36M
▲ +3.2% YoY
Op. Margin
-8021.40%
ROIC
-67.28%
▲ +1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$27M
▲ +5.6% YoY
Op. Cash Flow (TTM)
-$27M
▲ +5.7% YoY
Net Debt
-$36M
Net Cash Position
Cash & Equiv.
$36M
Continue Research